Fig. 2: PEG-A1 treatment reduces OIR-induced retinal dysfunction, limits loss of horizontal cells, and reduces PARP cleavage. | Cell Death & Disease

Fig. 2: PEG-A1 treatment reduces OIR-induced retinal dysfunction, limits loss of horizontal cells, and reduces PARP cleavage.

From: Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair

Fig. 2

A OIR reduced the retinal photopic B-wave ERG response at P50, which was partially rescued by PEG-A1 treatment. B OIR reduced visual acuity at P50 as measured by OptoMotry and this was rescued by PEG-A1 treatment. C, D Immunofluorescence labeling of P17 retinal sections with the horizontal cell marker Calbindin at P17 showed a decrease in numbers of horizontal cells in Vehicle-OIR retinas as compared to RA. PEG-A1 treatment reduced this loss. Scale bar = 50 µm. E, F Western blotting and quantification of P17 retinal lysates showed increased PARP cleavage in the OIR retinas, which was significantly reduced with PEG-A1 treatment.

Back to article page